Olema Pharmaceuticals, Inc.
OLMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001750284
In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Olema Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 67 | 66 | −1 |
| Shares | 33.3M | 33.4M | +81.2K (+0.2%) |
| Value | $81.6M | $116.1M | +$34.5M (+42.2%) |
New holders (7)
Institutions that held Olema Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 2,382,377 | $8.27M | 0.78% |
| Susquehanna International Group, LLP | 88,016 | $305.4K | 0.00% |
| Man Group plc | – | $124.3K | 0.00% |
| Squarepoint Ops LLC | 23,943 | $83.1K | 0.00% |
| HRT Financial LP | 19,644 | $68.0K | 0.00% |
| Citigroup Inc | 9,912 | $34.4K | 0.00% |
| Truvestments Capital LLC | 1,323 | $4.59K | 0.00% |
Sold out (8)
Institutions that held Olema Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Tang Capital Management LLC | 318,926 | $781.4K |
| Artal Group S.A. | 260,500 | $638.0K |
| New York Life Investment Management LLC | 133,157 | $326.2K |
| Anson Funds Management LP | 129,631 | $317.6K |
| Ergoteles LLC | 38,906 | $95.3K |
| Occudo Quantitative Strategies LP | 16,322 | $40.0K |
| Russell Investments Group, Ltd. | 11,991 | $29.4K |
| Running Point Capital Advisors, LLC | 10,000 | $24.5K |